Amundi Asset Management US’s Myriad Genetics MYGN Stock Holding History

Amundi Asset Management US’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$4.14M	Buy	+136,000	New	+$3.86M	﹤0.01%	1055
2020 Q2	–	Sell	-7,000	Closed	-$100K	–	1662
2020 Q1	$100K	Hold	7,000	–	–	﹤0.01%	1434
2019 Q4	$191K	Hold	7,000	–	–	﹤0.01%	1486
2019 Q3	$200K	Buy	7,000 +1,500	+27%	+$43.7K	﹤0.01%	1457
2019 Q2	$153K	Hold	5,500	–	–	﹤0.01%	1515
2019 Q1	$183K	Buy	+5,500	New	+$167K	﹤0.01%	1452
2018 Q4	–	Sell	-15,400	Closed	-$708K	–	1646
2018 Q3	$708K	Buy	+15,400	New	+$685K	﹤0.01%	1309

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GCM

Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return

Amundi Asset Management US's MYGN Position: Q1 2021 in Review

Amundi Asset Management US opened a new position in Myriad Genetics (MYGN) in Q1 2021: 136,000 shares worth $4.14M. The stake represents ﹤0.01% of the portfolio and ranks #1055 among its holdings. This is a return to the name: Amundi Asset Management US previously reported a position in MYGN as recently as Q1 2020.

Amundi Asset Management US first reported a position in MYGN in Q3 2018 and has held it in 7 quarters since. 197 funds tracked by Wall St. Rank hold MYGN as of Q1 2021.

Amundi Asset Management US held 136,000 shares of Myriad Genetics worth $4.14M as of Q1 2021.
Myriad Genetics was a new Amundi Asset Management US position in Q1 2021.
Myriad Genetics made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1055 holding.
Amundi Asset Management US first reported a position in Myriad Genetics in Q3 2018 and has held it in 7 quarters since.
197 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.